Estrogen Patch

What it is

An estrogen patch is a small adhesive square or oval worn on the lower abdomen, hip, or buttock that releases a steady, controlled dose of 17β-estradiol — the same molecule the ovaries made before menopause — through the skin into the bloodstream.

Because the hormone enters the body transdermally, it does not pass through the liver first (the "first-pass effect"). This is the central reason transdermal estradiol is preferred over oral estrogen for many patients, particularly anyone with elevated baseline risk for blood clots, migraine with aura, high triglycerides, or gallbladder disease.

FDA-approved estrogen patches in the United States include weekly options (Climara, Menostar, Climara Pro) and twice-weekly options (Vivelle-Dot, Minivelle, Alora, Estraderm, Dotti, CombiPatch).

How it works

The patch releases estradiol continuously over 3–4 days (twice-weekly patches) or 7 days (weekly patches), maintaining steady blood levels rather than the peaks and troughs seen with oral dosing.

Restored estradiol stabilizes the hypothalamic thermoregulatory center, dramatically reducing hot flashes and night sweats — typically by 75–80% within 8–12 weeks (NAMS 2022).

Transdermal delivery also protects bone mineral density, restores vaginal tissue, and supports sleep architecture and mood for many patients.

Who it's for

• Healthy women under 60 or within 10 years of menopause onset with bothersome vasomotor symptoms
• Patients with elevated VTE (clot) risk factors — obesity, smoking history, family history of clotting
• Women with migraine with aura (oral estrogen is contraindicated; transdermal generally is not)
• Patients with high triglycerides, gallbladder disease, or known liver impairment
• Women who prefer once- or twice-weekly dosing over a daily pill

Who should not take it

• Personal history of breast cancer or other estrogen-sensitive cancer
• Active or recent blood clot, stroke, or heart attack
• Unexplained vaginal bleeding
• Active liver disease
• Known or suspected pregnancy

Common side effects

• Mild skin irritation, redness, or itching at the patch site (rotate sites to minimize)
• Breast tenderness, mild bloating, or headache during the first 4–6 weeks
• Spotting or breakthrough bleeding, especially during the first 3–6 months on a combined regimen
• Occasional patch adhesion issues with swimming, sweating, or hot showers — most modern patches stay on through normal activity

Evidence summary

• NAMS 2022 Position Statement: transdermal estradiol is preferred over oral estrogen in patients with elevated cardiovascular or thrombotic risk; both routes reduce hot flash frequency by 75–80%.
• Endocrine Society 2015 Clinical Practice Guideline: transdermal estrogen is associated with a lower risk of venous thromboembolism than oral estrogen.
• ESHRE/IMS 2016: transdermal estradiol does not appear to increase VTE risk above baseline in observational and randomized data.
• Canonico et al. 2019 (BMJ): meta-analysis confirming roughly 2x VTE risk with oral estrogen vs no significant increase with transdermal.

FAQ

Sources

• NAMS 2022 Hormone Therapy Position Statement
• ACOG: Menopausal Symptom Management
• U.S. Food & Drug Administration
• Endocrine Society 2015 Clinical Practice Guideline — Menopause Hormone Therapy
• International Menopause Society 2016 Recommendations

Other medications

This page is educational and is not a substitute for a clinical evaluation. Whether any medication is appropriate for you depends on your full medical history. Kindr providers make individualized prescribing decisions during a clinical visit.